Tesamorelin + Ipamorelin: Pairing an Approved GHRH With a Ghrelin Agonist
A single-vial blend pairing FDA-approved GHRH analog Tesamorelin with the selective ghrelin-agonist Ipamorelin for a combined GH pulse in one injection.
What is Tesamorelin + Ipamorelin Blend?
A single-vial blend pairing Tesamorelin — a GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy and widely used off-label for GH-axis support — with Ipamorelin, a selective ghrelin-receptor-agonist GH secretagogue. Same combined-mechanism logic as the existing CJC-1295 (no-DAC) + Ipamorelin blend, using Tesamorelin as the GHRH-analog half instead of CJC-1295.
Quick facts
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| GH Axis Support | Bgrade | anchored on tesamorelin's FDA-approved GH-axis data; no trial of the combination |
Tesamorelin + Ipamorelin Blend Mechanism of Action
GHRH Analog + Selective Ghrelin Agonist
Tesamorelin is a GHRH analog that stimulates the pituitary's own GHRH receptor to release growth hormone in a physiological, pulsatile pattern — it's the only FDA-approved compound in this combination, approved as Egrifta for HIV-associated lipodystrophy. Ipamorelin works through a separate receptor, the ghrelin receptor, triggering an independent GH pulse. Hitting both receptors at once is the same combined-mechanism logic behind REGEN's existing CJC-1295 (no-DAC) + Ipamorelin blend, substituting Tesamorelin as the GHRH-analog half.
Why Pair a GHRH Analog with a Ghrelin Agonist
Because GHRH and ghrelin signal through distinct pituitary receptor pathways, combining an analog of each produces a larger GH pulse than either alone — a well-established pharmacological principle in GH secretagogue research, though it doesn't guarantee proportionally larger downstream benefits without dedicated combination-trial data.
Tesamorelin + Ipamorelin Blend Dosage and Protocols
Combined Dosing Protocol
Following each component's individual standard dosing: Tesamorelin 1–2mg subcutaneous once daily, and Ipamorelin 200–300mcg subcutaneous 1–3x daily. As with the CJC-1295 + Ipamorelin blend, dosing is typically timed around fasted states (e.g. pre-bed) to align with the body's natural nighttime GH pulse.
Tesamorelin + Ipamorelin Blend Side Effects and Safety
Combined Component Risk Profile
Tesamorelin's FDA label documents injection-site reactions, joint pain/arthralgia, and peripheral edema as the most common effects, plus a mild reduction in glucose tolerance in some patients — worth monitoring via fasting glucose/HbA1c. Ipamorelin's ghrelin-receptor mechanism is generally considered the most selective (fewest off-target effects) among GH secretagogues. Active malignancy and pregnancy are contraindicated given the GH/IGF-1 axis stimulation shared by both components.
Tesamorelin + Ipamorelin Blend Research Evidence
Strong Individual Data, No Combination Trial
Tesamorelin has the strongest evidence base of any compound in REGEN's GH-secretagogue category — it's FDA-approved based on multiple Phase 3 placebo-controlled trials in HIV-associated lipodystrophy. Ipamorelin has solid mechanistic and animal/early human pharmacology data as a selective ghrelin-receptor agonist. Neither compound, however, has been studied in combination in a controlled trial — the blend's rationale rests on complementary receptor mechanisms, not combination-specific trial data.
Regulatory and Legal Status
This blend is sold exclusively as a research-grade compound and is not approved for human consumption as a combined product — Tesamorelin itself is FDA-approved as Egrifta for a specific indication, but the combined blend sold by research-peptide vendors is not an FDA-approved product. Researchers and users should verify the legal status of this blend in their jurisdiction prior to purchase or use.
Tesamorelin + Ipamorelin Blend Stacking and Combinations
An Alternative to the CJC-1295 + Ipamorelin Blend
This blend serves a similar role to REGEN's existing CJC-1295 (no-DAC) + Ipamorelin blend, and researchers generally choose one or the other rather than combining both — Tesamorelin's FDA-approval history gives it the stronger individual safety/efficacy record, while CJC-1295 (no-DAC) has a shorter, more classically "pulsatile" pharmacokinetic profile.
Tesamorelin + Ipamorelin Blend Pharmacokinetics
Two Independent Clearance Profiles
Tesamorelin and Ipamorelin clear independently rather than sharing a unified half-life — no published pharmacokinetic study exists for the combined blend as a product, only for each compound individually.
Contraindications
- active malignancy
- pregnancy
Frequently asked questions
What is a typical Tesamorelin + Ipamorelin Blend dose?
Published research protocols report Tesa 1–2 mg · Ipa 200–300 mcg, Tesa 1x daily · Ipa 1-3x daily. This is the range described in the literature, not a recommendation.
Is Tesamorelin + Ipamorelin Blend backed by strong evidence?
Tesamorelin + Ipamorelin Blend carries a REGEN research grade of B. REGEN Research Tier B — observational human data (cohort / case studies).
How is Tesamorelin + Ipamorelin Blend administered?
Routes reported in the literature: subcutaneous.
Who should avoid Tesamorelin + Ipamorelin Blend?
Contraindications noted in the literature include active malignancy, pregnancy.